Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment

Hyperglycemia in T2DM is based on three main mechanisms: insulin resistance, progressive β-cell dysfunction, and excess glucose production by the liver.

The onset of T2DM is usually preceded by a long period of insulin resistance. Prescribing sugar drugs that affect different links of pathogenesis, reducing a steady decrease in glycemia. To date, in clinical practice, various combinations of hypoglycemic drugs are used, the choice of which is determined by the characteristics of the course of diabetes in the patient, the presence of concomitant diseases and complications of diabetes, as well as the dominant clinical problem. This resolution provides an expert council opinion on the feasibility of using a combination of alogliptin and pioglitazone in patients with type 2 diabetes.

1. Shestakova MV, Vikulova OK, Zheleznyakova AV, et al. Diabetes epidemiology in Russia: What has changed over the decade? Ter Arkh. 2019;91(10):4-13. doi: https://doi.org/10.26442/00403660.2019.10.000364

2. Waugh J, Keating GM, Plosker GL, et al. Pioglitazone: A review of its use in type 2 diabetes mellitus. Drugs. 2006;66(1):85-109. doi: https://doi.org/10.2165/00003495-200666010-00005

3. Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. Diabetes Mellitus. 2019;22(S1):1-144 (In Russ.). doi: https://doi.org/10.14341/DM221S1

4. Tan MH, Baksi А, Krahulec В, et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care. 2005;28(3):544-550. doi: https://doi.org/10.2337/diacare.28.3.544.

5. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspectivepioglitAzone clinical trial in macroVascular events): a randomised controlled trial. Lancet. 2005;366(9493):1279-1289. doi: https://doi.org/10.1016/S0140-6736(05)67528-9.

6. Feng J, Zhang Z, Wallace MB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007;50(10):2297-2300. doi: https://doi.org/10.1021/jm070104l

7. Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 2007;49(17):1772-1780. doi: https://doi.org/10.1016/j.jacc.2006.12.048

8. Wilcox R, Bousser MG, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspectivepioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007;38(3):865-73. doi: https://doi.org/10.1161/01.STR.0000257974.06317.49

9. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. J Am Med Assoc. 2007;298(10):1180-1188. doi: https://doi.org/10.1001/jama.298.10.1180

10. Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med. 2016;374(14):1321-1331. doi: https://doi.org/10.1056/NEJMoa1506930.

11. Young LH, Viscoli CM, Curtis JP, et al. Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack. Circulation. 2017;135(20):1882-1893. doi: https://doi.org/10.1161/CIRCULATIONAHA.116.024863

12. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370(9593):1129-1136. doi: https://doi.org/10.1016/S0140-6736(07)61514-1.

13. Eldor R, DeFronzo RA, Abdul-Ghani M. In vivo actions of peroxisome proliferator-activated receptors: Glycemic control, insulin sensitivity, and insulin secretion. Diabetes Care. 2013;36(2):S162. doi: https://doi.org/10.2337/dcS13-2003

14. Clarke GD, Solis-Herrera C, Molina-Wilkins M, et al. Pioglitazone improves left ventricular diastolic function in subjects with diabetes. Diabetes Care. 2017;40(11):1530-1536. doi: https://doi.org/10.2337/dc17-0078

15. Rosenstock J, Inzucchi SE, Seufert J, et al. Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes. Diabetes Care. 2010;33(11):2406-2408. doi: https://doi.org/10.2337/dc10-0159

16. Bosi E, Ellis GC, Wilson CA, Fleck PR. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes, Obes Metab. 2011;13(12):1088-1096. doi: https://doi.org/10.1111/j.1463-1326.2011.01463.x

17. DeFronzo RA, Burant CF, Fleck P, et al. Efficacy and Tolerability of the DPP-4 Inhibitor Alogliptin Combined with Pioglitazone, in Metformin-Treated Patients with Type 2 Diabetes. J Clin Endocrinol Metab. 2012;97(5):1615-1622. doi: https://doi.org/10.1210/jc.2011-2243

18. Van Raalte DH, van Genugten RE, Eliasson B, et al. The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes. Eur J Endocrinol. 2014;170(4):565-574. doi: https://doi.org/10.1530/EJE-13-0639